Illumina

ILMN

Precision medicineHealthcare diagnosticsGenomic analysis

$278.17vs prev close▲+13.60(+5.14%)

$88.0052W Range$309.35

86% from low

+65.01 (+31.78%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

2 sells

Concentrated sells

1M net buy

-$29.8M

≈ -115K shares

Portfolio Weight

1.40%

1M +0.23%p

Holding ETFs

2 ETFs

ARKG · ARKK

Buy · Weight Up

ARK net-bought the stock and the price rose, increasing its portfolio weight.

Shares +15.8% · Market value +53.5% · Weight +0.23%p

Trade Intensity

Minor adjustment

Basis: weight +0.23%p increase

Trade Log2-day SELL streak

Date	Action	ETF	Shares	Close	Est. total
26.10.08	SELL	ARKK	105,321	$264.57	$27.9M
26.09.14	SELL	ARKK	9,327	$208.21	$1.9M
26.08.19	SELL	ARKK	15,613	$205.00	$3.2M
26.08.18	SELL	ARKK	32,648	$188.29	$6.1M
26.07.29	SELL	ARKK	2,917	$194.82	$568.3K
26.07.20	SELL	ARKK	16,027	$184.68	$3.0M
26.07.16	SELL	ARKK	28,117	$190.25	$5.3M
26.07.08	SELL	ARKG · ARKK	52,418	$187.81	$9.8M
26.07.07	SELL	ARKG · ARKK	40,787	$191.76	$7.8M
26.07.02	SELL	ARKK	21,279	$188.68	$4.0M
26.06.11	SELL	ARKK	46,265	$166.21	$7.7M
26.03.26	SELL	ARKK	14,418	$124.40	$1.8M
26.03.25	SELL	ARKK	31,986	$126.20	$4.0M
26.02.03	SELL	ARKK	6,564	$135.43	$889.0K
26.02.02	SELL	ARKK	4,274	$141.13	$603.2K

10.08SELL

105,321

ARKKClose$264.57Est. total$27.9M

09.14SELL

9,327

ARKKClose$208.21Est. total$1.9M

08.19SELL

15,613

ARKKClose$205.00Est. total$3.2M

08.18SELL

32,648

ARKKClose$188.29Est. total$6.1M

07.29SELL

2,917

ARKKClose$194.82Est. total$568.3K

07.20SELL

16,027

ARKKClose$184.68Est. total$3.0M

07.16SELL

28,117

ARKKClose$190.25Est. total$5.3M

07.08SELL

52,418

ARKG · ARKKClose$187.81Est. total$9.8M

07.07SELL

40,787

ARKG · ARKKClose$191.76Est. total$7.8M

07.02SELL

21,279

ARKKClose$188.68Est. total$4.0M

06.11SELL

46,265

ARKKClose$166.21Est. total$7.7M

03.26SELL

14,418

ARKKClose$124.40Est. total$1.8M

03.25SELL

31,986

ARKKClose$126.20Est. total$4.0M

02.03SELL

6,564

ARKKClose$135.43Est. total$889.0K

02.02SELL

4,274

ARKKClose$141.13Est. total$603.2K

1 / 5

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

826,813

Portfolio Weight

1.4%

in ETF 4.62%

Est. Value

$243M

30D Net

-$30M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Targets

avg.

$233.55

vs Current ▼ -16.0% downside

Current$278.17

Low ~ High$113.00 ~ $365.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Barclays

Underweight

$200.00

-28.10%

$267.76

Maintain

2026-10-07

RBC Capital

Outperform

$310.00

+11.44%

$293.69

Maintain

2026-10-05

Guggenheim

Buy

$305.00

+9.65%

$265.72

Maintain

2026-10-01

Leerink Partners

Outperform

$300.00

+7.85%

$272.00

Maintain

2026-09-29

Piper Sandler

Overweight

$305.00

+9.65%

$271.90

Maintain

2026-09-28

1 / 4

Avg Target

$233.55

vs Current ▼ -16.0% downside

Buy

21 analysts

Strong Buy 4Buy 7Hold 6Sell 2Strong Sell 2

Low $113.00

Current $278.17

High $365.00

Firm	Position	Target	Upside	Close	Action	Date
Barclays	Underweight	$200.00	-28.10%	$267.76	Maintain	26.10.07
RBC Capital	Outperform	$310.00	+11.44%	$293.69	Maintain	26.10.05
Guggenheim	Buy	$305.00	+9.65%	$265.72	Maintain	26.10.01
Leerink Partners	Outperform	$300.00	+7.85%	$272.00	Maintain	26.09.29
Piper Sandler	Overweight	$305.00	+9.65%	$271.90	Maintain	26.09.28

1 / 4

Price Information

Previous Close$264.57

Open$268.21

Day Range$265.25 - $278.59

52-Week Range$88.00 - $309.35

1-Year Change192.72%

Trading Volume

Volume1,895,816

Avg Volume (3mo)2,699,576

Valuation

Market Cap42.0B

Book Value$18.80

Shares Outstanding151,000,000

Financials

Revenue (TTM)4.5B

Net Income824.0M

EPS$5.36

EBITDA1.2B

Profitability

P/E Ratio51.90

P/B Ratio14.80

Return on Equity (ROE)32.34%

Return on Assets (ROA)8.67%

Profit Margin18.34%

EV/EBITDA37.54

Beta1.42

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)66.22

Company Overview

Illumina, Inc. is a global leader in providing advanced sequencing and array-based solutions for genetic and genomic analysis. Their main products include instruments, consumables like reagents and flow cells, and various sequencing kits for whole genomes or targeted regions. Illumina serves a broad market including research centers, academic institutions, hospitals, and pharmaceutical and biotechnology companies.

P/B

14.80

High valuation

ROE

32.3%

High return

Beta

1.42

Market Volatility

RSI(14)

66.2

Neutral zone

AI-generated summary. Not investment advice.

Illumina

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks